Cargando…

Seven Weeks of High-Dose Vitamin D Treatment Reduces the Need for Infliximab Dose-Escalation and Decreases Inflammatory Markers in Crohn’s Disease during One-Year Follow-Up

Background: Seven weeks of high-dose vitamin D treatment decreases intestinal IL17A and IFN-γ mRNA expression in active Crohn’s disease (CD). In this follow-up study, we investigated whether seven-week vitamin D treatment affected the infliximab response in the following 45 weeks compared to placebo...

Descripción completa

Detalles Bibliográficos
Autores principales:	Bendix, Mia, Dige, Anders, Jørgensen, Søren Peter, Dahlerup, Jens Frederik, Bibby, Bo Martin, Deleuran, Bent, Agnholt, Jørgen
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8065492/ https://www.ncbi.nlm.nih.gov/pubmed/33810258 http://dx.doi.org/10.3390/nu13041083

Ejemplares similares

Decrease in Mucosal IL17A, IFNγ and IL10 Expressions in Active Crohn’s Disease Patients Treated with High-Dose Vitamin D Alone or Combined with Infliximab
por: Bendix, Mia, et al.
Publicado: (2020)

Vitamin D increases programmed death receptor-1 expression in Crohn’s disease
por: Bendix, Mia, et al.
Publicado: (2017)

Infliximab Induces Clonal Expansion of γδ-T Cells in Crohn's Disease: A Predictor of Lymphoma Risk?
por: Kelsen, Jens, et al.
Publicado: (2011)

Effect of elemental diet combined with infliximab dose escalation in patients with Crohn's disease with loss of response to infliximab: CERISIER trial
por: Hisamatsu, Tadakazu, et al.
Publicado: (2018)

Effects of Anti-TNFα Treatment on Mucosal Expression of IL-17A, IL-21, and IL-22 and Cytokine-Producing T Cell Subsets in Crohn's Disease
por: Dige, Anders, et al.
Publicado: (2018)

Highest Frequencies of Interleukin-22-Producing T Helper Cells in Alcoholic Hepatitis Patients with a Favourable Short-Term Course
por: Støy, Sidsel, et al.
Publicado: (2013)

Efficacy and Safety of Escalation of Adalimumab Therapy to Weekly Dosing in Pediatric Patients with Crohn's Disease
por: Dubinsky, Marla C., et al.
Publicado: (2016)

Adalimumab Dose-Escalation Therapy Is Effective in Refractory Crohn's Disease Patients with Loss of Response to Adalimumab, Especially in Cases without Previous Infliximab Treatment
por: Suzuki, Taketo, et al.
Publicado: (2019)

Dose Escalation and Co-therapy Intensification Between Etanercept, Adalimumab, and Infliximab: The CADURA Study
por: Thorne, Carter, et al.
Publicado: (2017)

Ustekinumab dose escalation improves clinical responses in refractory Crohn’s disease
por: Haider, Syedreza A., et al.
Publicado: (2020)

Efficacy and safety of dose escalation of infliximab therapy in Japanese patients with psoriasis: Results of the SPREAD study
por: Torii, Hideshi, et al.
Publicado: (2016)

Efficacy of Infliximab Dose Escalation in Patients with Refractory Immunotherapy-Related Colitis: A Case Series
por: Harris, Jessica P, et al.
Publicado: (2022)

Low Dose Infliximab for Prevention of Postoperative Recurrence of Crohn’s Disease: Long Term Follow-Up and Impact of Infliximab Trough Levels and Antibodies to Infliximab
por: Sorrentino, Dario, et al.
Publicado: (2015)

Systematic Review and Meta-analysis: Loss of Response and Need for Dose Escalation of Infliximab and Adalimumab in Ulcerative Colitis
por: Savelkoul, Edo H J, et al.
Publicado: (2022)

Cost savings of anti-TNF therapy using a test-based strategy versus an empirical dose escalation in Crohn's disease patients who lose response to infliximab
por: Roblin, Xavier, et al.
Publicado: (2015)

Adalimumab vs Infliximab in Pediatric Patients With Crohn's Disease: A Propensity Score Analysis and Predictors of Treatment Escalation
por: Bronsky, Jiri, et al.
Publicado: (2022)

Baseline tumour necrosis factor alpha levels predict the necessity for dose escalation of infliximab therapy in patients with rheumatoid arthritis
por: Takeuchi, Tsutomu, et al.
Publicado: (2011)

Will savings from biosimilars offset increased costs related to dose escalation? A comparison of infliximab and golimumab for rheumatoid arthritis
por: Curtis, Jeffrey R., et al.
Publicado: (2019)

Effects of Arabinoxylan and Resistant Starch on Intestinal Microbiota and Short-Chain Fatty Acids in Subjects with Metabolic Syndrome: A Randomised Crossover Study
por: Hald, Stine, et al.
Publicado: (2016)

Complement activation capacity in plasma before and during high-dose prednisolone treatment and tapering in exacerbations of Crohn's disease and ulcerative colitis
por: Zimmermann-Nielsen, Erik, et al.
Publicado: (2005)

Infliximab in the treatment of Crohn’s disease
por: Poggioli, Gilberto, et al.
Publicado: (2007)

The IGF system in patients with inflammatory bowel disease treated with prednisolone or infliximab: potential role of the stanniocalcin-2 / PAPP-A / IGFBP-4 axis
por: Hjortebjerg, Rikke, et al.
Publicado: (2019)

Phase I Dose-Escalation Study of Once Weekly or Once Every Two Weeks Administration of High-Dose Sunitinib in Patients With Refractory Solid Tumors
por: Rovithi, Maria, et al.
Publicado: (2019)

Successful treatment of oral Crohn's disease by anti-TNF-alpha dose escalation - a case report
por: Bokemeyer, Arne, et al.
Publicado: (2018)

Dose Escalation Patterns of Advanced Therapies in Crohn’s Disease and Ulcerative Colitis: A Systematic Literature Review
por: Panaccione, Remo, et al.
Publicado: (2023)

The impact of induction therapy with three doses of infliximab on deep histological healing in paediatric patients with active Crohn’s disease
por: Szymanska, Edyta, et al.
Publicado: (2016)

Administration of Panobinostat Is Associated with Increased IL-17A mRNA in the Intestinal Epithelium of HIV-1 Patients
por: Bjerg Christensen, Ane, et al.
Publicado: (2015)

Randomised phase II study comparing dose-escalated weekly paclitaxel vs standard-dose weekly paclitaxel for patients with previously treated advanced gastric cancer
por: Shitara, K, et al.
Publicado: (2014)

High Dose Infliximab in the Treatment of Refractory Uveitis: Does Dose Matter?
por: Sukumaran, Sukesh, et al.
Publicado: (2012)

Infliximab to treat Crohn’s disease: an update
por: Cottone, M, et al.
Publicado: (2011)

Free antibodies-to-infliximab are biomarker for predicting the effect of dose intensification in pediatric Crohn’s disease patients with secondary loss of response
por: Kim, Eun Sil, et al.
Publicado: (2023)

Dose escalation of a curcuminoid formulation
por: Lao, Christopher D, et al.
Publicado: (2006)

The relationship between infliximab concentrations, antibodies to infliximab and disease activity in Crohn's disease
por: Vande Casteele, Niels, et al.
Publicado: (2015)

Serum Levels of Infliximab and Anti-Infliximab Antibodies in Brazilian Patients with Crohn's Disease
por: Gomes, Luis Eduardo Miani, et al.
Publicado: (2019)

Efficacy and safety of tofacitinib dose de‐escalation and dose escalation for patients with ulcerative colitis: results from OCTAVE Open
por: Sands, Bruce E., et al.
Publicado: (2019)

Profile of infliximab in the treatment of pediatric Crohn’s disease
por: Kierkus, Jaroslaw, et al.
Publicado: (2015)

Metastatic Crohn’s disease despite infliximab therapy
por: Campos, Sara, et al.
Publicado: (2017)

Myelolipoma After Infliximab Treatment for Crohn's Disease
por: Cesa, Kevin, et al.
Publicado: (2022)

Infliximab for medical induction of remission in Crohn's disease
por: Gordon, Morris, et al.
Publicado: (2023)

Radiation treatment planning with embedded dose escalation
por: Hrinivich, William T., et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_a0r2rkk6gqos0c2lpu1rdpa3dr